Organon Exempts Four States from 340B Contract Pharmacy Restrictions

October 15 is the deadline for Medicare Part D prescription drug notices and extended Form 5500 filings (if a Form 5558 was filed). Employers should act now to stay compliant. Read more: https://bit.ly/3KoiXMR #EmployeeBenefits #MedicarePartD #Form5500 📝 Juliana Reno | Lisa Tavares | Ryann M. Aaron, Esq.

Fifth Circuit upholds Mississippi’s 340B contract-pharmacy protections. Bottom line: manufacturer contract pharmacy policies face continued restrictions in Mississippi. Alan Arville, Chris Smith, and Rachael Grey break down takings and preemption implications for multistate strategies. #340B #HealthLaw #Appellate

P4AD Patient Advocate Judy from Maine is saving money at the pharmacy thanks to the 2022 prescription drug law's $2,000 cap on out of pocket drug costs. With that savings, Judy and her husband are able to breathe a little easier while tackling other expenses. Are you seeing savings on your prescription costs thanks to the 2022 prescription drug law? Share your story today: https://lnkd.in/ezRxWPQ7

📢 Montana pharmacies: changes are coming your way as Montana is reclassifying Gabapentin as Schedule V controlled substance. Our Senior Director of Regulatory Operations, Mitch Lamb, Pharm.D, has summarized the important changes for you to be prepared for below. 🚀 Stay ahead of regulatory changes with D2's #ComplySuite® and the #RegComply™ module! Supported directly by Mitch and his team, RegComply delivers: ✅ Custom regulatory alert triaging  ✅ In-app legislative tracking ✅ Proactive task population and action documentation Stay ahead of the change. Learn more about D2's ComplySuite » https://lnkd.in/eFtquCZU #Pharmacy #DeliveringBetter #HealthcarePolicy

Pharmacies Feeling the Squeeze 💊💸 Rising demand for GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) is colliding with low reimbursement rates—and pharmacies are losing money. Coverage is shrinking, prior authorizations are piling up, and some independent pharmacies are reconsidering whether to stock these high-demand medications. Read the full story on how reimbursement challenges are reshaping access and pharmacy practice: https://lnkd.in/e78RFG7g #PharmacyNews #GLP1 #Wegovy #Zepbound #IndependentPharmacy #PharmacyChallenges #MedicationAccess #HealthcareNews

In today’s Medicare Minute, I talk about Prescription Drug plans and their volatility as we head into ‘26. Enrollment opens on October 15!

FDA just dropped a wave of Untitled and Warning Letters on prescription drug promotion, calling out lifestyle imagery, selective QoL claims, and even distracting visuals. Compounded GLP-1 promotions weren't spared either. Read our recent blog post written by Dara Katcher Levy and Sarah Wicks where they provide some high level thoughts on the CDER ad/pro letters released yesterday. https://lnkd.in/e6H4TA7a #thefdalawblog #FDA #OPDP #ADPROMO

FDA’s Crackdown on Rx Drug Promotion Ramps Up with Release of Letters This is a great overview of the large volume of Untitled and Warning letters the FDA posted on September 9th on prescription drug promotion.

Deadline approaching! Plan sponsors must provide creditable coverage disclosure notices to Medicare-eligible individuals to alert them as to whether their prescription drug coverage is creditable each year before October 15. In an article on our blog, we review the most common questions about disclosure requirements: https://brev.is/zwFrm